Drug Trial Radar · NCT00611026
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
Last checked: Nov 20, 2026Latest source record: Feb 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,417
Actual
Start
Feb 2008
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Conditions
- Overactive Bladder
Interventions
Tolterodine ERDrug
The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
PlaceboDrug
Placebo treatment will be once daily(QD) for 12 weeks.
FesoterodineDrug
The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12Time frame: Baseline, Week 12
Locations
227 sites in 25 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Enterprise, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Chandler, Arizona
Pfizer Investigational Site
Peoria, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Anaheim, California
Pfizer Investigational Site
Clovis, California
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Torrance, California
Pfizer Investigational Site
Upland, California
Pfizer Investigational Site
Vista, California
Pfizer Investigational Site
Westlake Village, California
Pfizer Investigational Site
Englewood, Colorado
Pfizer Investigational Site
New London, Connecticut
Pfizer Investigational Site
Bonita Spring, Florida
Pfizer Investigational Site
Hollywood, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Lake Worth, Florida
Pfizer Investigational Site
Leesburg, Florida
Pfizer Investigational Site
Longwood, Florida
Pfizer Investigational Site
Loxahatchee Groves, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Naples, Florida
Pfizer Investigational Site
Pembroke Pines, Florida
Pfizer Investigational Site
Stuart, Florida
Pfizer Investigational Site
Tallahassee, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Meridian, Idaho
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Peoria, Illinois
Pfizer Investigational Site
Avon, Indiana
Pfizer Investigational Site
Evansville, Indiana
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.